UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of oncology, 2021-01, Vol.32 (1), p.49-57

2021

Volltextzugriff (PDF)

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Annals of oncology, 2023-06, Vol.34 (6), p.531-542

2023

Volltextzugriff (PDF)

Downsizing der adjuvanten Therapie für Brustkrebspatientinnen aus dem Mammografie-Screening-Programm (MSP)

Geburtshilfe und Frauenheilkunde, 2018, Vol.78 (10)

Uleer, C

2018

Volltextzugriff (PDF)

Nachsorge, Rezidivtherapie, psychoonkologische Versorgung und Palliativmedizin des Endometriumkarzinoms

Gynäkologe (Berlin), 2018-12, Vol.51 (12), p.1037-1046

2018

Volltextzugriff (PDF)

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii703-viii703

2018

Volltextzugriff (PDF)

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of oncology, 2014-01, Vol.25 (1), p.75-80

2014

Volltextzugriff (PDF)

1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO

European journal of cancer (1990), 2015-09, Vol.51, p.S288-S289

2015

Volltextzugriff (PDF)

313P Intrinsic subtypes in a cohort of early breast cancer patients

Annals of oncology, 2023-10, Vol.34, p.S309-S309

2023

Volltextzugriff (PDF)

284P Prognostic and predictive impact of uPA/PAI-1 in early breast cancer

Annals of oncology, 2023-10, Vol.34, p.S297-S297

2023

Volltextzugriff (PDF)

295P ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients

Annals of oncology, 2023-10, Vol.34, p.S302-S302

2023

Volltextzugriff (PDF)

297P Prognostic and predictive impact of NOTCH1 in early breast cancer

Annals of oncology, 2023-10, Vol.34, p.S303-S303

2023

Volltextzugriff (PDF)

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Annals of oncology, 2014-12, Vol.25 (12), p.2363-2372

2014

Volltextzugriff (PDF)

176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Annals of oncology, 2020-09, Vol.31, p.S313-S313

2020

Volltextzugriff (PDF)

389TiP - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Annals of oncology, 2019-10, Vol.30, p.v142-v142

2019

Volltextzugriff (PDF)

389TiPPRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Annals of oncology, 2019-10, Vol.30, p.v142

2019

Volltextzugriff (PDF)

Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-08

2019

Volltextzugriff (PDF)

Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system

European journal of cancer (1990), 2020-10, Vol.138, p.S68-S68

2020

Volltextzugriff (PDF)

Abstract P1-15-10: A prospective multicenter real-world study on neoadjuvant treatment and clinical outcome in TNBC patients

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-15-10

2019

Volltextzugriff (PDF)

Abstract P2-05-12: The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-05-12

2017

Volltextzugriff (PDF)

Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-06-06

2018

Volltextzugriff (PDF)

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS5-06-GS5-06

2019

Volltextzugriff (PDF)

LBA13Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results

Annals of oncology, 2017-09, Vol.28, p.v606-v606

2017

Volltextzugriff (PDF)

Androgenrezeptor (AR) und Forkhead BoxA1 (FOXA1) als Prognosefaktoren beim frühen HER2-negativen Mammakarzinom – eine translationale Substudie im Rahmen der prospektiven Phase-III-WSG-Plan B Studie

Geburtshilfe und Frauenheilkunde, 2016, Vol.76 (10)

2016

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(44)
Deutsch
(13)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Downsizing der adjuvanten Therapie für Brustkrebspatientinnen aus dem Mammografie-Screening-Programm (MSP)

Nachsorge, Rezidivtherapie, psychoonkologische Versorgung und Palliativmedizin des Endometriumkarzinoms

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO

313P Intrinsic subtypes in a cohort of early breast cancer patients

284P Prognostic and predictive impact of uPA/PAI-1 in early breast cancer

295P ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients

297P Prognostic and predictive impact of NOTCH1 in early breast cancer

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

389TiP - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

389TiPPRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO

Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system

Abstract P1-15-10: A prospective multicenter real-world study on neoadjuvant treatment and clinical outcome in TNBC patients

Abstract P2-05-12: The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)

Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

LBA13Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results

Androgenrezeptor (AR) und Forkhead BoxA1 (FOXA1) als Prognosefaktoren beim frühen HER2-negativen Mammakarzinom – eine translationale Substudie im Rahmen der prospektiven Phase-III-WSG-Plan B Studie

Suchergebnisse filtern